News

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology…

2 years ago

Maylands Dental Centre Launch Free Dental Implant and Invisalign Consultations

Maylands, Australia, May 11, 2023 (GLOBE NEWSWIRE) -- Maylands Dental Centre is a Dentist Perth that has recently launched free implant and…

2 years ago

Admire Dental Butler: Dentist In Butler Launches New Website Under New Management

Butler, Australia, May 11, 2023 (GLOBE NEWSWIRE) -- Admire Dental Butler, a dental clinic that provides a range of oral…

2 years ago

South Perth Dental Surgery: Dentist In South Perth Announces New Customised Dental Implant Solutions

South Perth, Australia, May 11, 2023 (GLOBE NEWSWIRE) -- Founded in 1991, South Perth Dental Surgery is an established Dentist South…

2 years ago

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines…

2 years ago

Better Choice Appoints Kent Cunningham as Chief Executive Officer

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet…

2 years ago

Sirona Biochem: Investing News Network Interview with CSO, Dr. Geraldine Deliencourt-Godefroy

An In-Depth Look at Anti-Aging Compound TFC-1326VANCOUVER, British Columbia, May 11, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM)…

2 years ago

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- metastatic breast cancer, with no dose-limiting toxicities, and no…

2 years ago

Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Pivotal top-line data readout expected in mid-2023WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon”…

2 years ago

Venus Concept Announces 1-for-15 Reverse Stock Split

TORONTO, May 11, 2023 (GLOBE NEWSWIRE) --  Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical…

2 years ago